Cingulate shares are trading higher after the company announced it received guidance from the FDA regarding its clinical program for CTx-1301. Based on the guidance, the company expects to submit the NDA for CTx-1301 in the first half of 2025.
Portfolio Pulse from Benzinga Newsdesk
Cingulate Inc. shares have risen following the announcement that the company received guidance from the FDA on its CTx-1301 clinical program. The company anticipates submitting the New Drug Application (NDA) for CTx-1301 in the first half of 2025.
December 28, 2023 | 3:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cingulate Inc. has received positive guidance from the FDA for its CTx-1301 clinical program, which is a significant step towards the submission of an NDA expected in the first half of 2025.
The positive news from the FDA regarding the clinical program for CTx-1301 is likely to be viewed favorably by investors, as it suggests a clear regulatory path forward and potential for market entry. This can lead to increased investor confidence and a potential short-term rise in Cingulate's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100